Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70391 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Fabian Maximilian Meinert und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology and Toxicology, Charité-Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anti-Arrhythmia Agents, Anticoagulants, Ischemic Stroke. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
Our international cohort study assessed the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) among patients with non‐valvular atrial fibrillation (NVAF) using antiarrhythmic drugs.
Methods
Using the United Kingdom's (UK's) Clinical Practice Research Datalink Aurum and Québec claims data, we assembled two study cohorts of patients with NVAF who initiated DOACs or VKAs while on antiarrhythmic drugs (2011–2020). Using an as‐treated exposure definition, we assessed the risks of ischemic stroke and major bleeding associated with DOACs vs . VKAs. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) after propensity score‐based inverse‐probability‐of‐treatment‐weighting. Site‐specific estimates were pooled together using random‐effects models. Secondary analyses assessed effect measure modification by individual DOAC and type of antiarrhythmic drugs (interacting vs . non‐interacting).
Results
The study cohort included 44 435 patients with NVAF initiating DOACs (n = 29 071) or VKAs (n = 15 364) while using antiarrhythmics. Compared to VKAs, DOACs were not associated with the risk of ischemic stroke (UK: HR, 0.90; 95% CI, 0.61–1.32/ Quebec: HR, 0.85; 95% CI, 0.70–1.03/ pooled: HR, 0.86; 95% CI 0.72–1.02; I 2 = 0%) but with a decreased risk of major bleeding (UK: HR, 0.90; 95% CI, 0.75–1.08/Quebec: HR, 0.83; 95% CI, 0.76–0.91/pooled: HR 0.84; 95% CI 0.78–0.92; I 2 = 0%); the latter was more pronounced with apixaban (pooled HR, 0.71; 95% CI, 0.63–0.81; I 2 = 74%). There was no effect modification by type of antiarrhythmic drugs.
Conclusions
DOACs were as effective but safer than VKAs among NVAF patients treated with antiarrhythmic drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Pharmacology and Toxicology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Department of Medicine, McGill University, Montreal, Quebec, Canada.
- Centre for Clinical Epidemiology, Lady Davis Institute, Montreal, Quebec, Canada.
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
- Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
ORCID-Profile: Kristian B Filion, Christel Renoux, Antonios Douros
Zitieren
APA
Meinert, F. M., Dimakos, J., Cui, Y., Filion, K. B., Renoux, C., & Douros, A. (2025). Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70391
Vancouver
Meinert FM, Dimakos J, Cui Y, Filion KB, Renoux C, Douros A. Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70391
BibTeX
@article{Meinert2025,
author = {Meinert, Fabian Maximilian and Dimakos, Jenny and Cui, Ying and Filion, Kristian B and Renoux, Christel and Douros, Antonios},
title = {Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70391}
}
EUVIMED